Sjogren's Syndrome - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Sjogren's Syndrome - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Sjogren's Syndrome - Pipeline Review, H1 2015', provides an overview of the Sjogren's Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sjogren's Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sjogren's Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Sjogren's Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Sjogren's Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Sjogren's Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Sjogren's Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Sjogren's Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Sjogren's Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Sjogren's Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Sjogren's Syndrome - Overview 8
Pipeline Products for Sjogren's Syndrome - Comparative Analysis 9
Sjogren's Syndrome - Therapeutics under Development by Companies 10
Sjogren's Syndrome - Therapeutics under Investigation by Universities/Institutes 11
Sjogren's Syndrome - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Sjogren's Syndrome - Products under Development by Companies 15
Sjogren's Syndrome - Products under Investigation by Universities/Institutes 16
Sjogren's Syndrome - Companies Involved in Therapeutics Development 17
Aegera Therapeutics Inc. 17
Amgen Inc. 18
Bristol-Myers Squibb Company 19
MedImmune, LLC 20
Novartis AG 21
Takeda Pharmaceutical Company Limited 22
Toleranzia AB 23
Sjogren's Syndrome - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
abatacept (recombinant) - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ABS-11 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AMG-557 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Cell Therapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CFZ-533 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Coversin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
IMSO-001 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MEDI-4920 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
MLN-3126 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NS-2 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Recombinant Protein for Sjogren's Syndrome - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
VAY-736 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Sjogren's Syndrome - Recent Pipeline Updates 51
Sjogren's Syndrome - Dormant Projects 56
Sjogren's Syndrome - Discontinued Products 57
Sjogren's Syndrome - Product Development Milestones 58
Featured News & Press Releases 58
Mar 24, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Sjogren-Larsson Syndrome Phase II Clinical Trial 58
Mar 17, 2015: Aldeyra Therapeutics Opens Enrollment in Sjogren-Larsson Syndrome Clinical Trial and Finalizes Noninfectious Anterior Uveitis Clinical Trial Protocol 58
Mar 02, 2015: Aldeyra Therapeutics Provides Update on NS2 Clinical Program 58
Jan 29, 2015: Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Sjogren-Larsson Syndrome at the 2015 Society for Inherited Metabolic Disorders Annual Meeting 59
Jan 26, 2015: Aldeyra Therapeutics to Participate in Canaccord Genuity Rare Disease, BioPharma One-on-One Day 60
Jan 05, 2015: Aldeyra Therapeutics Submits IND Filing to FDA for Clinical Testing of NS2 in Patients With Sjogren-Larsson Syndrome 60
Dec 16, 2014: Aldeyra Therapeutics Abstract Accepted at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting 60
Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren's syndrome 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables

Number of Products under Development for Sjogren's Syndrome, H1 2015 8
Number of Products under Development for Sjogren's Syndrome - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Sjogren's Syndrome - Pipeline by Aegera Therapeutics Inc., H1 2015 17
Sjogren's Syndrome - Pipeline by Amgen Inc., H1 2015 18
Sjogren's Syndrome - Pipeline by Bristol-Myers Squibb Company, H1 2015 19
Sjogren's Syndrome - Pipeline by MedImmune, LLC, H1 2015 20
Sjogren's Syndrome - Pipeline by Novartis AG, H1 2015 21
Sjogren's Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 22
Sjogren's Syndrome - Pipeline by Toleranzia AB, H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Sjogren's Syndrome Therapeutics - Recent Pipeline Updates, H1 2015 51
Sjogren's Syndrome - Dormant Projects, H1 2015 56
Sjogren's Syndrome - Discontinued Products, H1 2015 57